Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2011-07-19
2011-07-19
Kemmerer, Elizabeth C. (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100
Reexamination Certificate
active
07981420
ABSTRACT:
The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system. Furthermore, the invention provides for the use of a modulator of a polypeptide having or comprising said amino acid sequence of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with angiogenic disorders or disorders of the cardio-vascular system. In addition the invention provides for the use of said polypeptide or said functional fragment or derivative thereof for the preparation of a pharmaceutical composition for preventing or treating tumor growth or formation of tumor metastases or as a marker of stem cells.
REFERENCES:
patent: 6864239 (2005-03-01), Peri et al.
patent: 7094761 (2006-08-01), Peri et al.
patent: 7439063 (2008-10-01), Digicaylioglu et al.
patent: 7498034 (2009-03-01), Bicknell et al.
patent: 7524492 (2009-04-01), Sharma
patent: 7582440 (2009-09-01), Bicknell et al.
patent: 2003/0087394 (2003-05-01), Sharma
patent: 2003/0212001 (2003-11-01), Peri et al.
patent: 2004/0038292 (2004-02-01), Burslem et al.
patent: 2004/0071711 (2004-04-01), Bicknell et al.
patent: 2004/0092444 (2004-05-01), Digicaylioglu et al.
patent: 2005/0059604 (2005-03-01), Peri et al.
patent: 2005/0197284 (2005-09-01), Digicaylioglu et al.
patent: 2006/0292613 (2006-12-01), Peri et al.
patent: 2007/0025913 (2007-02-01), Bicknell et al.
patent: 2007/0122491 (2007-05-01), Lyons et al.
patent: 2007/0155687 (2007-07-01), Lyons et al.
patent: 2007/0253946 (2007-11-01), Yamashita et al.
patent: 2008/0004255 (2008-01-01), Lyons et al.
patent: 2008/0008692 (2008-01-01), Lyons et al.
patent: 2008/0081337 (2008-04-01), Sharma
patent: 2008/0105705 (2008-05-01), Schmidt
patent: 2008/0135582 (2008-06-01), Schmidt
patent: 2008/0145359 (2008-06-01), Bicknell et al.
patent: 2008/0160034 (2008-07-01), Brennan et al.
patent: 2008/0213791 (2008-09-01), Freije et al.
patent: 2008/0219924 (2008-09-01), Bicknell et al.
patent: 2008/0274045 (2008-11-01), Bicknell et al.
patent: 2008/0279859 (2008-11-01), Mezler et al.
patent: 2009/0028852 (2009-01-01), Herrera et al.
patent: 2009/0093409 (2009-04-01), Digicaylioglu et al.
patent: 2009/0191572 (2009-07-01), Bicknell et al.
patent: 2009/0220588 (2009-09-01), Edelman et al.
patent: 2009/0220589 (2009-09-01), Trieu et al.
patent: 2009/0269356 (2009-10-01), Epstein et al.
patent: 2009/0311253 (2009-12-01), Ghayur et al.
patent: 2010/0183588 (2010-07-01), Plouet et al.
patent: WO 96/13518 (1996-05-01), None
patent: WO 0073801 (2000-12-01), None
patent: 2006054000 (2006-05-01), None
patent: 2007141258 (2007-12-01), None
patent: 2008087224 (2008-07-01), None
patent: 2009006543 (2009-01-01), None
patent: 2009140383 (2009-11-01), None
patent: 2010006060 (2010-01-01), None
patent: 2010006184 (2010-01-01), None
patent: 2010006189 (2010-01-01), None
patent: 2010007144 (2010-01-01), None
Stokes et al., Experimental modeling of human spinal cord injury: a model that crosses the species barrier and mimic the spectrum of human cytopathology, Spinal Cord 40: 101-109, 2002.
Talac et al. Animal models of spinal cord injury for evaluation of tissue engineering treatment strategies, Biomaterials 25: 1505-1510, 2004.
Mills et al. Strain and model differences in behavioral outcomes after spinal cord injury in rat,J. Neurotrauma Aug;18(8):743-56, 2001.
Mautes et al. Vascular events after spinal cord injury: contribution to secondary pathogenesis. Phys Ther. Jul. 2000;80(7):673-87.
Kuby 1997. Immunology, Third Edition, pp. 131-134.
Alberts et al. 1994. Molecular Biology of the Cell, Third Edition, pp. 1216-1220.
Beaud ML et al. 2008. BMC Neurosci. 9: 5.
Giger RJ et al. 2008. Restorative Neurol Neurosci. 26: 97-115.
Hunt D et al. 2002. J Neurocytol. 31: 93-120.
Iseda T et al. 2008. J Neurotrauma. 25: 334-349.
Müller BK et al. Curr Biol. 1996, 6(11): 1497-1502.
Steward O et al. 2008. Exp Neurol. 209: 446-468.
Hata et al., 2006, Journal of Cell Biology, 173(1): 47-58.
Tassew, N.G. et al., “Sustained In Vivo Inhibition of Protein Domains Using Single-Chain Fv Recombinant Antibodies and Its Application to Dissect RGMa Activity on Axonal Outgrowth,” The Journal of Neuroscience, Jan. 28, 2009, 29(4): 11126-1131.
Matsunaga, E. et al., “Repulsive Guidance Molecule Plays Multiple Roles in Neuronal Differentiation and Axon Guidance,” The Journal of Neuroscience, May 31, 2006, 26(22):6082-6088.
Fitzgerald, D.P. et al.,Neogeninis expressed on neurogenic and gliogenic progenitors in . . . Gene Expr. Pattern (2007), 7:784-792.
D.P. Fitzgerald, et al., Characterization of neogenin-expressing neural progenitor populations and migrating neuroblasts in the embryonic mouse forebrain, Neuroscience (2006), 142(3): 703-16.
Muller, B.K., et al., “Chromophore-assisted laser inactivation of a repulsive axonal guidance molecule,” Current Biology 1996, vol. 6 No. 11:1497-1502.
Muller, B.K., et al., “In Vitro Experiments on Axonal Guidance and Growth-Cone Collapse,” J. Exp. Biol. 153, 29-46 (1990).
Kyoto, et al., , “Synapase formation of the cortico-spinal axons is enhanced by RGMa inhibition after spinal cord injury,” Brain Research (2007), 1186:74-86.
GenomeQuest—Sequence Search Report result Feb. 15 11:32 am dated Feb. 15, 2010.
GenomeQuest—Sequence Search Report result Feb. 15 11:32 am (redo 1) dated Feb. 15, 2010.
FTO RGM-A Sequence search dated Feb. 15, 2010.
RGM-A human isoform 1 NP—001159755 Blast search dated Feb. 15, 2010.
B. Mueller et al., “RGM, a repulsive guidance molecule, is involved in retinal axon guidance in vitro.” Taniguchi Symposia on Brain Sciences, vol. 20 Mol. Basis of Axon Growth & Nerve Pattern Form 1997, pp. 215-229.
J. Frisen et al., “Ephrin-A5 (AL-1/RAGS) is essential for proper retinal axon guidance and topographic mapping in the mammalian visual system” Neuron, vol. 20, No. 2, Feb. 1998, pp. 235-243.
Letter dated Dec. 23, 1998 from Bernhard Mueller to Dr. Thomas Hesse reporting on the results of research performed during a sabbatical relating to RGM during Jul. 29, 1998 to Sep. 6, 1998. (English translation).
Anderson Jens S.
Bonhoeffer Friedrich
Macchi Paolo
Mann Matthias
Monnier Philippe P.
Ballard Kimberly A.
Kemmerer Elizabeth C.
Max-Planck-Gesellschaft zur Foederung der Wissenschaften e.V.
Mueller Lisa V.
Polsinelli Shughart PC
LandOfFree
Therapeutic use of antibodies directed against repulsive... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic use of antibodies directed against repulsive..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use of antibodies directed against repulsive... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698978